

DAFTAR PUSTAKA

1. WHO. 2019. Early Diagnosis and Screening of Breast Cancer. <https://www.who.int/cancer/prevention/diagnosis-screening/breast-cancer/en/>. Diakses 18 september,2019.
2. IARC. 2018. *Global Cancer Observatory*. <https://gco.iarc.fr/today/data/factsheets/populations/360-indonesia-factsheets.pdf>. Diakses 19 september,2019.
3. ACS. 2019. What Is Breast Cancer ?. <https://www.cancer.org/cancer/breast-cancer/about/what-is-breast-cancer.html>. Diakses 18 september,2019.
4. Jamnasil J, Gondhowiardjo, Soehartati, Djoerban Z, Siregar NC, Poetiray EDC, et al. 2016. Faktor risiko terjadinya metastasis jauh pada pasien kanker payudara. *J Indones Radiat Oncol Soc*. 7(2):55-59.
5. Pulido C, Vendrell I, Ferreira AR, Casimiro S, Mansinho A, Alho I, et al. 2017. Bone metastasis risk factors in breast cancer. *Ecanc Med Science*.
6. Purushotham A. 2014. Age at diagnosis and distant metastasis in breast cancer. *Eur J Cancer*. 50(10):1697-1705.
7. Ekpe E, Shaikh A, Shah J, Jacobson J, Sayed S, et al. Metastatic Breast Cancer in Kenya: Presentation, Pathologic Characteristics, and Patterns. *J Glob Oncol*. 2018.
8. Güth U, Magaton I, Huang DJ, Fisher R, Schötzaue A, Vetter M. 2014. Primary and secondary distant metastatic breast cancer: Two sides of the same coin. *Breast*. 23(1):26-32.
9. Xiao W, shaoquan Zheng, Yang A, Zhang X, Zou Y, Tang H, et al. Breast cancer subtypes and the risk of distant metastasis at initial diagnosis: a population-based study. *Dovepress*. 2018;10:5329–38.
10. Kementerian Kesehatan RI. 2018 . Pedoman Nasional Pelayanan Kedokteran Tata Laksana Kanker Payudara. <http://kanker.kemkes.go.id/guidelines/PNPKPayudara.pdf>. Diakses 16 oktober,2019.
11. Jin X, Mu P. 2015. Targeting breast cancer metastasis. *Breast Cancer (Auckl)*. 9:23-34.
12. Gonzalez-Angulo A, Litton J, Broglio K, Meric-Bernstam F, Rakhit R, Cardoso F. 2009. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. *J Clin Oncol*. 27(34):5700-6.
13. Guntari GAS, Suariyani NLP. 2016. Gambaran fisik dan psikologis penderita kanker payudara post mastektomi di RSUP Sanglah Denpasar tahun 2014. *Arch Com Heal*. 3(1):24-35.
14. Suzanna E, Sirait T, Rahayu P, Shalmont G, Anwar E, Raden A. 2012. Registrasi Kanker Berbasis Rumah Sakit di Rumah Sakit Kanker Dharmais (Pusat Kanker Nasional). *Indones J Cancer*. 6:1-12.

15. Carlson R, Allred D, Anderson B, Burstein H. 2009. Breast Cancer. *J Natl Compr Canc Netw*. 7:122-192.
16. Stavros A. 2004. *Breast Imaging Ultrasound*. 1st ed. (Williams L, Wilken, eds.). Philadelphia.
17. ACS. 2012. Breast cancer : early detection. <https://www.cancer.org/content/dam/CRC/PDF/Public/8579.00.pdf>. Diakses 20 september, 2019.
18. Klein S. 2005. Evaluation of Palpable Breast Masses. *Am Fam Physician*. 71:1731-38.
19. Disha E, Kerliu S, Ymeri H, Kutliovci A. 2009. Comparative Accuracy of Mammography And Ultrasound in Women With Breast Symptomp According to ages and breast density. *Bosn J Basic Med Sci*. 9(2):131-6.
20. Hille H, Chilinger R. 2008. *Breast Ultrasound*. Vol 4.
21. Breast cancer classification. <http://www.wikipedia.ogr/wiki/BreastCancer>. Diakses 8 november,2019.
22. Lakhani S, Marc J, Jocelyn J, Thomas J, Peter P, Lesley M, et al. 2017. The Pathology of Familial Breast Cancer: Predictive Value of Immunohistochemical Markers Estrogen Receptor, Progesterone Receptor, HER-2, and p53 in Patients With Mutations in BRCA1 and BRCA2. *J Clin Oncol*. 20(9):2310–8.
23. Simon R, Nocito A, Hübscher T. 2001. Patterns of HER-2/neu Amplification and Overexpression in Primary and Metastatic Breast Cancer. *JNCI*. 93(15):1141-46.
24. Inwald E.C. 2012. Ki-67 is Prognostic Parameter in Breast Cancer Patients : results of a large population-based cohor of a cancer registry. *Breast Cancer Res Treat*. 193:539-52.
25. Stuart J Schnitt. 2010. Classification and prognosis of invasive Breast cancer: from morphology to molecular toxonomy. *Dep Pathol Beth Isr Deaconess Med Cent Harvard Med Sch*.
26. Breast Cancer. <https://www.breastcancer.org/symptoms/diagnosis/invasive>. Published 2012.
27. Brunicardi, FC. 2015. *Schwartz's Principles of Surgery*. 10th ed. New York:McGrawHill.
28. Colzani E. 2014. Time-dependent risk of developing distant metastasis in breast cancer patients according to treatment, age and tumour characteristics. *Br J Cancer*. 110(5):1378-84.
29. Coleman RE, Smith P, Rubens RD. 1998. Clinical course and prognostic factors following bone recurrence from breast cancer. *Br J Cancer*. 77(2):336-40.
30. Diessner J. 2016. Evaluation of clinical parameters influencing the

development of bone metastasis in breast cancer. *BMC Cancer*. 16(307). doi:10.1186/s12885-016-2345-7

31. Liede A, Jerzak KJ, Hernandez RK, Wade S, Sun P, Narod SA. 2016. The incidence of bone metastasis after early-stage breast cancer in Canada. *Breast Cancer Res Treat*. 3(156):587-95.
32. Hofbauer L. 2014. Endocrine aspects of bone metastases *Lancet Diabetes Endocrinol*. *Lancet Diabetes Endocrinol*. 2(6):500-12.
33. Imkampe A, Bates T. 2010. Impact of a raised body mass index on breast cancer survival in relation to age and disease extent at diagnosis. *Breast J*. 16(2):156-61.
34. Yazici O. 2015. The effect of obesity on recurrence pattern in early breast cancer patients. *J Buon*. 20(4):954-62.
35. Chan D. 2014. Body mass index and survival in women with breast cancer-systematic literature review and metaanalysis of 82 follow-up studies. *Ann Onc*. 25(10):1901-14.
36. Huszno J, Nowara E. 2015. Risk factors for disease progression in HER2-positive breast cancer patients based on the location of metastases. *Prz Menopauzalny*. 13(3):173-77.
37. Gong Y, Zhang J, Ji P, Ling H, Hu X, Shao Z-M. 2018 .Incidence proportions and prognosis of breast cancer patients with bone metastases at initial diagnosis. *Cancer Med*. 7(8):4156-69.
38. Liu Y, Zhang J, Huang R, Feng WL, Kong YN, Xu F, Zhao L, et al. 2017. Influence of occupation and education level on breast cancer stage at diagnosis, and treatment options in China: a nationwide, multicenter 10-year epidemiological study. *Medicine (Baltimore)*. 96(15). doi: 10.1097/MD.0000000000006641.
39. Chen J. 2013. Analysis of clinicopathological factors associated with bone metastasis in breast cancer. *J Huazhong Univ Sci Tech Med Sci*. 33(1):122-5.
40. James J. 2003. Bone metastases from breast carcinoma: histopathological - radiological correlations and prognostic features. *Br J Cancer*. 89(4):660-5.
41. Mathew A, Padma S, Rajagopal, Vilgran V, Gurprataap S, Brufsky A. 2017. Distinct Pattern of Metastases in Patients with Invasive Lobular Carcinoma of the Breast. *Geburtshilfe Frauenheilkd*. 77(6):660-6.
42. Yamashiro H. 2014. Prevalence and risk factors of bone metastasis and skeletal related events in patients with primary breast cancer in Japan. *Int J Clin Oncol*. 19(5):852-62.
43. Wei B. Bone metastasis is strongly associated with estrogen receptor-positive/progesterone receptor-negative breast carcinomas *Hum Pathol* 39(12) 1809–15.
44. Meisner A, Fekrazad M, Royce M. 2008. Breast disease: benign and malignant. *Med Clin North Am*. 92(5):1115-41.

45. Feig S. 1986. The role of new imaging modalities in staging and follow-up of breast cancer. *Semin Oncol.* 13:402-14.
46. Osborne C. 1998. Steroid hormone receptors in breast cancer management. *Breast Cancer Res Treat.* 227-38.
47. Cologne. 2016. Metastatic breast cancer: Overview. *Inst Qual Effic Heal Care.*
48. Bergh J, Jansson T, Ahlstrom H. 1993. Positron emission tomography (PET) for diagnosis and rapid therapy evaluation on breast cancer patients. *Proc Annu Meet Am Soc Clin Oncol.* 12:250.
49. Eubank W, Mankoff D, Takasugi J. 2001. 18 fluorodeoxyglucose positron emission tomography to detect mediastinal or internal mammary metastases in breast cancer. *J Clin Oncol.* 19:3516-23.
50. Hathaway P, Mankoff D, Maravilla K. 1999. Value of combined FDG PET and MR imaging in the evaluation of suspected recurrent local-regional breast cancer. *Radiology.* 210:807-14.
51. Hortobagyi G. 1998. Treatment of breast cancer. *N Engl J Med.* 339:974-84.
52. Brunnicardi, FC. 2015. *Schwartz's Principles of Surgery.* Vol 100.
53. Valastyan S, Weinberg R. 2011. Tumor metastasis: molecular insights and evolving paradigms. *Cell.* 147:275-92.
54. Guo W, Giancotti F. 2004. Integrin signalling during tumour progression. *Nat Rev Mol Cell Biol.* 5:816-26.
55. Gay L, Felding-Habermann B. 2011. Contribution of platelets to tumour metastasis. *Nat Rev Cancer.* 11:123-34.
56. Gupta G, Massague J. 2006. Cancer metastasis: building a framework. *Cell.* 127:679-95.
57. Chen L, Yang S, Jakoncic, J, Zhang J, Huang X. Migrastatin analogues target fascin to block tumour metastasis. *Nature.* 464:1062-66.
58. Nguyen D, Bos P, Massague J. 2009. Metastasis: from dissemination to organspecific colonization. *Nat Rev Cancer* 9:274-84.
59. Zhang X, Wang Q, Gerald W. 2009. Latent bone metastasis in breast cancer tied to Src-dependent survival signals. *Cancer Cell.*16:67-78.
60. Chen Q, Zhang X, Massague J. 2011. Macrophage binding to receptor VCAM-1 transmits survival signals in breast cancer cells that invade the lungs. *Cancer Cell.* 20:538-49.
61. Weilbaecher K, Guise T, McCauley L. 2011. Cancer to bone: a fatal attraction. *Nat Rev Cancer.* 11:411-25.
62. Mundy G. 2002. Metastasis to bone: causes, consequences and therapeutic opportunities. *Nat Rev Cancer.* 2:584-93.

63. Acharyya S, Oskarsson T, Vanharanta S. 2012. CXCL1 paracrine network links cancer chemoresistance and metastasis. *Cell*. 150:165-78.
64. Margolese R, Hortobagyi G, Buchholz T. 2003. Management of Metastatic Breast Cancer.
65. Rivera E, Holmes F, Buzdar A. 2002. Fluorouracil, doxorubicin, and cyclophosphamide followed by tamoxifen as adjuvant treatment for patients with stage IV breast cancer who have no evidence of disease. *Breast J*. 8:2-9.
66. Body J, Coleman R, Piccart M. 1996. Use of bisphosphonates in cancer patients. *Cancer Treat Rev*. 22:265-87.
67. Largillier R, Ferrero JM, Doyen J, Barriere J, Namer M, Mari V, et al. 2008. Prognostic factors in 1038 women with metastatic breast cancer. *Ann Oncol*. 19(12):2012-19.
68. Devita Jr. VT, Lawrence TS, Rosenberg SA. 2019. *Cancer Principles & Practice of Oncology*. 11th ed. (Shaw R, ed.). Wolters Kluwer.
69. Soerjomataram I, Louwman M, Ribot J, Roukeman J, Coebergh J. 2008. An overview of prognostic factors for long-term survivors of breast cancer. *Breast Cancer Res Treat*. 107:309-30.
70. Cianfrocca M, Goldstein L. 2004. Prognostic and Predictive Factors in Early Stage Breast Cancer. *Oncologist*. 9:606-16.
71. Pushpalatha K, Idrisinghe, Thike A, Cheok P, Tse G, Lui P. 2010. Hormone Receptor and c-ERBB2 Status in Distant Metastatic and Locally Recurrent Breast Cancer. *Am J Clin Pathol*. 133:416-29.
72. Lin C, Chien S, Chen L, Kuo S, Chang T, Chen D. 2009. Triple Negative Breast Carcinoma is a Prognostic Factor in Taiwanese Woman. *BMC Cancer*. 9:192. doi:10.1186/1471-2407-9-192
73. Sastroasmoro S. 2012. Dasar-dasar metodologi penelitian klinis. 4th ed. Sagung S, editor. Jakarta.
74. Wikipedia. Pendidikan di Indonesia. https://id.wikipedia.org/wiki/Pendidikan_di_Indonesia. Diakses 19 Oktober 2019.
75. Ambang indeks Massa tubuh. 2019. Kemenkes RI. <http://www.p2ptm.kemkes.go.id/infographic-p2ptm/obesitas/tabel-batas-ambang-indeks-massa-tubuh-imt>. Diakses 20 Oktober 2019.
76. Sjamsuhidajat R, De Jong W, editors. 2017. Buku Ajar ilmu bedah Sjamsuhidajat-De Jong. 4th ed. Jakarta: Penerbit Buku Kedokteran EGC. 481–513 p.
77. Investigation O, Hortobagyi GN, Connolly JL, D’Orsi CJ, Edge SB, Mittendorf EA, et al. 2017. AJCC Cancer Staging Manual, Eighth Edition: Breast. Vol. 39, Cancer Treatment Reviews. 1355–1359 p.

78. Howlader N, Cronin KA, Kurian AW, Andridge R. Differences in Breast Cancer Survival by Molecular Subtypes in the United States. *Cancer Epidemiol Biomarkers Prev.* 2018;27(6):619-626.
79. Minn AJ, Kang Y, Serganova I, Gupta GP, Giri DD, Doubrovin M, et al. 2005. Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors. *JCI.* 115:44–55.
80. Müller A, Homey B, Soto H. Involvement of chemokine receptors in breast cancer metastasis. *Nature.* 2001;410:50-56.
81. Bruce J, Carter DC, Fraser J. Patterns of recurrent disease in breast cancer. *Lancet.* 1970;295(7644):433-435.
82. Protokol Peraboi. 2003.
83. Rahmi F. Hubungan Kadar Cancer Antigen 15-3 Serum Dengan Metastasis Pada Kanker Payudara. 2019.
84. Chen M-T, Sun H-F, Zhao Y, et al. 2017. Comparison of patterns and prognosis among distant metastatic breast cancer patients by age groups: a SEER population-based analysis. *Sci Rep.* 7:9254.
85. Kim HJ, Ahn SG, Lee HM, et al. 2015. Metastasis-Free Interval Is Closely Related to Tumor Characteristics and Has Prognostic Value in Breast Cancer Patients with Distant Relapse. *J Breast Cancer.* 18(4):371.
86. Cox T, Erler J. 2011. Remodeling and homeostasis of the extracellular matrix: implications for fibrotic diseases and cancer. *Dis Model Mech.* 4(2):165-178.
87. Barroso-Sousa R, Metzger-Filho O. 2016. Differences between invasive lobular and invasive ductal carcinoma of the breast: results and therapeutic implications. *Ther Adv Med Oncol.* 25;8(4):261–6.
88. Korhonen T, Kuukasjärvi T, Huhtala H, Alarmo E, Holli K, Kallioniemi A, et al. 2013. The impact of lobular and ductal breast cancer histology on the metastatic behavior and long term survival of breast cancer patients. *Breast.* 22(6):1119–24.
89. Taheri M, Tavakol M, Akbari M, Anoshirvani A, Aghabozorgi R, Almasi-Hashiani A, et al. 2019. Socioeconomic inequalities in metastasis, recurrence, stage and grade of breast cancer: a hospital-based retrospective cohort study. *J Prev Med Hyg.* 60(3):262–9.
90. Setyowati I. Hubungan Antara Pengetahuan, Sikap dan Perilaku Pencegahan dengan Kejadian Kanker Payudara di RSUD Dr. Moewardi. 2012.
91. Saleh K, Carton M, Dieras VC, Heudel PE, Brain E, Firmin N, et al. 2019. Prognostic impact of body mass index (BMI) on overall survival in patients with metastatic breast cancer. *Ann Onc.* 30:5. doi :<https://doi.org/10.1093/annonc/mdz242.062>

92. Gennari A, Nanni O, Puntoni M, DeCensi A, Scarpi E, Conte P, et al. 2013. Body Mass Index and Prognosis of Metastatic Breast Cancer Patients Receiving First-Line Chemotherapy. *Cancer Epidemiol Biomarkers Prev* . 1;22(10):1862–7.
93. Sander M. 2011. Profil Penderita Kanker Payudara Stadium Lanjut Baik Lokal Maupun Metastasis Jauh Di Rsup Hasan Sadikin Bandung. *Farmasains*. 1(2):1-3.
94. Robbins S, Cotran R. *Pathologic Basis of Disease*. 2005. 7th ed. Pennsylvania: Elsevier.
95. Minn AJ, Gupta GP, Padua D, Bos P, Nguyen DX, Nuyten D, et al. 2007. Lung metastasis genes couple breast tumor size and metastatic spread. *Proc Natl Acad Sci*. 17;104(16):6740–5.
96. Yusra V, Machmud R, Yenita. Faktor-faktor yang Berhubungan dengan Tingkat Pengetahuan Wanita Usia Subur Tentang “SADARI” di Nagari Painan. *J FK Unand*. 2016;5(3):697-704.
97. Park S, Han W, Kim J, Kim MK, Lee E, Yoo T-K, et al. 2015. Risk Factors Associated with Distant Metastasis and Survival Outcomes in Breast Cancer Patients with Locoregional Recurrence. *J Breast Cancer* . 18(2):160.
98. Kennecke H, Yerushalmi R, Woods R, Cheang M, Voduc D, Speers C, et al. 2010. Subtypes, Metastatic behavior of breast cancer. *J Clin Oncol*. 28(20):3271–7.
99. Sopik V, Narod SA. 2018. The relationship between tumour size, nodal status and distant metastases: on the origins of breast cancer. *Breast Cancer Res Treat* . 24;170(3):647–56.
100. Yue G, Yi-Rong L, Peng J, Xin H, Zhi-Ming S. 2017. Impact of molecular subtypes on metastatic breast cancer patients: a SEER population-based study. *Sci Rep*. 7(45411):1-3.
101. Kim J, Lee Y, Yoo T. 2019. Organ-Specific Recurrence or Metastatic Pattern of Breast Cancer according to Biological Subtypes and Clinical Characteristics. *J Breast Dis*. 7(1):30-37.
102. Martin AM, Cagney DN, Catalano PJ. 2017. Brain Metastases in Newly Diagnosed Breast Cancer. *JAMA Oncol*. 3(8):1069.
103. Yonemori K, Tsuta K, Ono M. 2010. Disruption of the blood brain barrier by brain metastases of triple-negative and basal-type breast cancer but not HER2/neu-positive breast cancer. *Cancer*. 116(2):302-308.
104. Van Poznak C, Somerfield MR, Bast RC. 2015. Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. *J Clin Oncol*. 33(24):2695-2704.

